LOXL2 and ovarian carcinoma: Our findings confirmed the molecular mechanism by which COL1A1-induced upregulation of LOXL2 promotes ovarian cancer metastasis through a positive feedback loop involving EGFR-MEK-ERK-SP1, offering novel scientific insights and potential therapeutic targets for inhibiting ovarian cancer metastasis.